Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr Pearse on the Current Treatment Paradigm for Relapsed/Refractory MCL

April 18th 2024

William B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.

Zanubrutinib Associated With Longer Treatment Persistence, Duration, and TTD in Real-World MCL

April 17th 2024

Real-world treatment with zanubrutinib was linked to longer treatment persistence, duration, and time to discontinuation in mantle cell lymphoma.

B-Cell Receptor Signaling Activity Portends Inferior Outcomes in MCL

April 17th 2024

B-cell receptor signaling characteristics were associated with worse outcomes in patients with mantle cell lymphoma.

Dr Pearse on the Utility of Pirtobrutinib in Relapsed/Refractory MCL

April 16th 2024

William B. Pearse, MD, discusses the current role of the BTK inhibitor pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

Dr Coombs on Noncovalent BTK Inhibitors in Relapsed/Refractory MCL

April 5th 2024

Catherine C. Coombs, MD, discusses the mechanism of action of noncovalent BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

Dr Goy on Real-World Outcomes With CAR T-Cell Therapy in MCL

March 29th 2024

Andre Goy, MD, discusses the implementation of CAR T-cell therapy in patients with relapsed/refractory mantle cell lymphoma.

CTL019 Plus Ibrutinib is Feasible and Effective in Relapsed/Refractory MCL

March 29th 2024

CTL019 CAR T-cell therapy plus time-limited ibrutinib resulted in high complete response rates in relapsed/refractory mantle cell lymphoma.

Dr Phillips on Ongoing Research in High-Risk MCL

March 28th 2024

Tycel Phillips, MD, MPH, discusses ongoing trials for patients with high-risk mantle cell lymphoma.

Observational Study Shows Frontline Ibrutinib With/Without Rituximab Is Safe and Effective in Low-Risk Mantle Cell Lymphoma

March 28th 2024

Ibrutinib with or without rituximab was effective and tolerable in patients with previously untreated, low-risk mantle cell lymphoma.

Dr Goy on Updated Data From ZUMA-2 With Brexu-Cel in MCL

March 27th 2024

Andre Goy, MD, discusses updated data from the phase 2 ZUMA-2 trial, highlighting the expanded-access ZUMA-18 study in MCL.

Brexu-Cel Displays Superior Responses vs Pirtobrutinib in Relapsed/Refractory MCL Matching-Adjusted Indirect Comparison

March 22nd 2024

A matching-adjusted indirect comparison shows that brexu-cel is superior to pirtobrutinib regarding response and survival in relapsed/refractory MCL.

EZH2 Expression and TP53 Mutation Results in Inferior Outcomes in MCL

March 21st 2024

TP53 mutation and EZH2 expression negatively affect outcomes in mantle cell lymphoma, with a synergistic negative effect.

FDA Lifts Partial Clinical Hold on Trial Evaluating NX-2127 in R/R B-Cell Malignancies

March 11th 2024

The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies

Dr Phillips on Efforts to Clarify and Refine Management Approaches in Relapsed/Refractory MCL

March 7th 2024

Tycel Phillips, MD, discusses efforts to clarify and refine the treatment paradigm of patients with mantle cell lymphoma.

Dr Phillips on Unmet Needs in Patients With Relapsed/Refractory MCL

March 5th 2024

Tycel Phillips, MD, discusses unmet needs for patients with relapsed/refractory mantle cell lymphoma.

Brexu-Cel Delivers Prolonged OS Benefit in Relapsed/Refractory MCL

February 28th 2024

Andre H. Goy, MD, discusses how the ZUMA-18 trial data support the benefit of earlier-line use of brexucabtagene autoleucel in mantle cell lymphoma.

Revisit Every OncLive On Air Episode From January 2024

February 26th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

Dr Moustafa on Standard Treatment Approaches in MCL

February 22nd 2024

Muhamad Alhaj Moustafa, MD, MS, discusses standard treatments for transplant-eligible and transplant-ineligible patients with mantle cell lymphoma.

Liso-Cel Proves Active Across High-Risk MCL Subgroups

February 22nd 2024

Liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features.

Dr Cohen on Treatment Considerations for Relapsed/Refractory MCL

February 21st 2024

Jonathon B. Cohen, MD, MS, discusses treatment considerations for mantle cell lymphoma and the role of pirtobrutinib in the management of this disease.